425 related articles for article (PubMed ID: 21419848)
21. Human TSC-associated renal angiomyolipoma cells are hypersensitive to ER stress.
Siroky BJ; Yin H; Babcock JT; Lu L; Hellmann AR; Dixon BP; Quilliam LA; Bissler JJ
Am J Physiol Renal Physiol; 2012 Sep; 303(6):F831-44. PubMed ID: 22791333
[TBL] [Abstract][Full Text] [Related]
22. Upregulation of 6-phosphofructo-2-kinase (PFKFB3) by hyperactivated mammalian target of rapamycin complex 1 is critical for tumor growth in tuberous sclerosis complex.
Wang Y; Tang S; Wu Y; Wan X; Zhou M; Li H; Zha X
IUBMB Life; 2020 May; 72(5):965-977. PubMed ID: 31958214
[TBL] [Abstract][Full Text] [Related]
23. Clinicopathological and immunohistochemical findings in an autopsy case of tuberous sclerosis complex.
Boer K; Troost D; Jansen F; Nellist M; van den Ouweland AM; Geurts JJ; Spliet WG; Crino P; Aronica E
Neuropathology; 2008 Dec; 28(6):577-90. PubMed ID: 18410267
[TBL] [Abstract][Full Text] [Related]
24. Loss of expression of tuberin and hamartin in tuberous sclerosis complex-associated but not in sporadic angiofibromas.
Fackler I; DeClue JE; Rust H; Vu PA; Kutzner H; Rütten A; Kaddu S; Sander CA; Volkenandt M; Johnson MW; Vinters HV; Wienecke R
J Cutan Pathol; 2003 Mar; 30(3):174-7. PubMed ID: 12641776
[TBL] [Abstract][Full Text] [Related]
25. mTORC1 enhancement of STIM1-mediated store-operated Ca2+ entry constrains tuberous sclerosis complex-related tumor development.
Peng H; Liu J; Sun Q; Chen R; Wang Y; Duan J; Li C; Li B; Jing Y; Chen X; Mao Q; Xu KF; Walker CL; Li J; Wang J; Zhang H
Oncogene; 2013 Sep; 32(39):4702-11. PubMed ID: 23108404
[TBL] [Abstract][Full Text] [Related]
26. The specificity and role of microglia in epileptogenesis in mouse models of tuberous sclerosis complex.
Zhang B; Zou J; Han L; Beeler B; Friedman JL; Griffin E; Piao YS; Rensing NR; Wong M
Epilepsia; 2018 Sep; 59(9):1796-1806. PubMed ID: 30079598
[TBL] [Abstract][Full Text] [Related]
27. Loss of Tsc2 in radial glia models the brain pathology of tuberous sclerosis complex in the mouse.
Way SW; McKenna J; Mietzsch U; Reith RM; Wu HC; Gambello MJ
Hum Mol Genet; 2009 Apr; 18(7):1252-65. PubMed ID: 19150975
[TBL] [Abstract][Full Text] [Related]
28. Urokinase-type plasminogen activator (uPA) is critical for progression of tuberous sclerosis complex 2 (TSC2)-deficient tumors.
Stepanova V; Dergilev KV; Holman KR; Parfyonova YV; Tsokolaeva ZI; Teter M; Atochina-Vasserman EN; Volgina A; Zaitsev SV; Lewis SP; Zabozlaev FG; Obraztsova K; Krymskaya VP; Cines DB
J Biol Chem; 2017 Dec; 292(50):20528-20543. PubMed ID: 28972182
[TBL] [Abstract][Full Text] [Related]
29. Biallelic TSC gene inactivation in tuberous sclerosis complex.
Crino PB; Aronica E; Baltuch G; Nathanson KL
Neurology; 2010 May; 74(21):1716-23. PubMed ID: 20498439
[TBL] [Abstract][Full Text] [Related]
30. Tuberous sclerosis complex and DNA repair.
Habib SL
Adv Exp Med Biol; 2010; 685():84-94. PubMed ID: 20687497
[TBL] [Abstract][Full Text] [Related]
31. A brain proteomic investigation of rapamycin effects in the
Wesseling H; Elgersma Y; Bahn S
Mol Autism; 2017; 8():41. PubMed ID: 28775826
[TBL] [Abstract][Full Text] [Related]
32. Tuberous sclerosis complex, implication from a rare genetic disease to common cancer treatment.
Inoki K; Guan KL
Hum Mol Genet; 2009 Apr; 18(R1):R94-100. PubMed ID: 19297407
[TBL] [Abstract][Full Text] [Related]
33. Tuberous sclerosis as an underlying basis for infantile spasm.
Yeung RS
Int Rev Neurobiol; 2002; 49():315-32. PubMed ID: 12040899
[TBL] [Abstract][Full Text] [Related]
34. [Tuberous Sclerosis Complex].
Kaneda M
Brain Nerve; 2019 Apr; 71(4):374-379. PubMed ID: 30988224
[TBL] [Abstract][Full Text] [Related]
35. Tsc2 mutation rather than Tsc1 mutation dominantly causes a social deficit in a mouse model of tuberous sclerosis complex.
Kashii H; Kasai S; Sato A; Hagino Y; Nishito Y; Kobayashi T; Hino O; Mizuguchi M; Ikeda K
Hum Genomics; 2023 Feb; 17(1):4. PubMed ID: 36732866
[TBL] [Abstract][Full Text] [Related]
36. Neuronal and glia abnormalities in Tsc1-deficient forebrain and partial rescue by rapamycin.
Carson RP; Van Nielen DL; Winzenburger PA; Ess KC
Neurobiol Dis; 2012 Jan; 45(1):369-80. PubMed ID: 21907282
[TBL] [Abstract][Full Text] [Related]
37. Metabotropic glutamate receptor-dependent long-term depression is impaired due to elevated ERK signaling in the ΔRG mouse model of tuberous sclerosis complex.
Chévere-Torres I; Kaphzan H; Bhattacharya A; Kang A; Maki JM; Gambello MJ; Arbiser JL; Santini E; Klann E
Neurobiol Dis; 2012 Mar; 45(3):1101-10. PubMed ID: 22198573
[TBL] [Abstract][Full Text] [Related]
38. Comparison of three rapamycin dosing schedules in A/J Tsc2+/- mice and improved survival with angiogenesis inhibitor or asparaginase treatment in mice with subcutaneous tuberous sclerosis related tumors.
Woodrum C; Nobil A; Dabora SL
J Transl Med; 2010 Feb; 8():14. PubMed ID: 20146790
[TBL] [Abstract][Full Text] [Related]
39. Renal disease in tuberous sclerosis complex: pathogenesis and therapy.
Lam HC; Siroky BJ; Henske EP
Nat Rev Nephrol; 2018 Nov; 14(11):704-716. PubMed ID: 30232410
[TBL] [Abstract][Full Text] [Related]
40. Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function.
Meikle L; Pollizzi K; Egnor A; Kramvis I; Lane H; Sahin M; Kwiatkowski DJ
J Neurosci; 2008 May; 28(21):5422-32. PubMed ID: 18495876
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]